GEN Exclusives

More »

GEN News Highlights

More »
Jul 25, 2007

Cell Therapeutics Acquires Systems Medicine in a $20M Transaction

  • Cell Therapeutics (CTI) reports that it is buying Systems Medicine (SMi) in a stock-for-stock merger valued at $20 million. SMi stockholders could receive a maximum of $15 million in additional consideration, payable in either cash or shares of CTI common stock, upon the achievement of certain regulatory milestones.

    CTI notes that one of the main highlights of this transaction is that SMi’s Phase II anticancer candidate, Brostallicin, will fill its pipeline gap. While CTI’s  pixantrone and Xyotax are in late-stage development with launches expected in the first and second half of 2009, respectively, SMi’s drug has the potential to receive market approval by 2010.

    Brostallicin is a DNA minor groove binding agent. "Brostallicin has a potentially unique ability to become more active in tumors that are resistant to other cancer drugs," according to Jack W. Singer, M.D., CMO at CTI. "The extensive preclinical profiling of this agent, coupled with the fact that the EORTC (European Organization for Research and Treatment of Cancer) has advanced Brostallicin to a randomized Phase II trial in first-line treatment of sarcoma as a result of a successful Phase II effort in patients with prior therapy, underscores the potential of this product."



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?